2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCN).
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCN).
Related Content: